Wednesday, 15 August 2018 - 9:57
  • it
  • de
  • en
  • fr

AMG 334

EMA accepts application for Novartis/Amgen’s migraine treatment

Novartis announced that EMA accepted its MAA (Marketing Authorization Application) for AMG 334 (erenumab) for the prevention of migraine. The drug is an anti-CGRP monoclonal antibody which binds selectively to the CGRP receptor, believed to play a critical role in…

Episodic migraine, positive results for Amgen/Novartis’ AMG 334

Novartis today announced positive results from ARISE, a Phase-III trial aimed at evaluating the efficacy and safety of monthly AMG 334 (erenumab) 70mg in episodic migraine prevention in 577 patients. The study met the primary endpoint, demonstrating a statistically significant…